Antifungal Susceptibility Patterns and Clinical Treatment Outcomes among Patients with Dermatophytosis: A Cross-Sectional Study
Naogaon Medical College Journal · 2026
DOI: 10.70818/nmcj.v03i01.028 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift Naogaon Medical College Journal, 2026. Verfasst von Shaila Zaman und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Dermatophytosis remains a widespread dermatological burden in South Asia, and rising antifungal resistance among Trichophyton species now threatens the reliability of first-line oral regimens across the region.
Objective
This study characterised in vitro antifungal susceptibility patterns and corresponding clinical treatment outcomes among culture-confirmed dermatophytosis patients attending a tertiary hospital in Joypurhat.
Methods
A hospital-based cross-sectional study enrolled 216 patients with clinicoetiologically confirmed dermatophytosis at the Department of Dermatology and Venereology, 400-Bedded General Hospital, Joypurhat, between January 2024 and June 2025. Direct microscopy, fungal culture, and broth microdilution-based minimum inhibitory concentration (MIC) testing against itraconazole, terbinafine, fluconazole, and griseofulvin were performed, and patients were followed through completion of prescribed antifungal therapy; data were analysed in SPSS v26.0.
Results
The cohort comprised 110 men (50.9%) and 106 women (49.1%), mean age 41.6 ± 14.0 years. Tinea corporis (32.9%) and tinea cruris (24.5%) predominated, and 128 patients (59.3%) had a history of topical corticosteroid misuse (tinea incognito). Trichophyton mentagrophytes/interdigitale complex was the leading isolate (57.4%), followed by T. rubrum (27.3%). In vitro sensitivity was preserved for itraconazole in 193 isolates (89.4%) and for terbinafine in 189 isolates (87.5%), while 13 isolates (6.0%) were itraconazole-resistant and 24 (11.1%) showed a terbinafine intermediate/resistance trend. Complete clinical and mycological cure was achieved in 178 patients (82.4%; 95% CI 77.3–87.5%), partial response in 28 (13.0%), and treatment failure in 10 (4.6%). Cure rates did not differ significantly by prior steroid misuse (67/88 [76.1%] vs 111/128 [86.7%]; χ2 = 3.33, p = 0.068) or by prescribed regimen (χ2 = 3.19, p = 0.363). Adverse events or early recurrence occurred in 7 patients (3.24%).
Conclusion
Itraconazole and terbinafine retain high in vitro activity against dermatophytes in this Joypurhat cohort, and outcome-based regimen selection remains clinically justified, though emerging resistant subsets warrant continued mycological surveillance.
Zitieren
APA
Zaman, S., Sattar, M. A., & Sumsuzzoha, S. (2026). Antifungal Susceptibility Patterns and Clinical Treatment Outcomes among Patients with Dermatophytosis: A Cross-Sectional Study. Naogaon Medical College Journal. https://doi.org/10.70818/nmcj.v03i01.028
Vancouver
Zaman S, Sattar MA, Sumsuzzoha S. Antifungal Susceptibility Patterns and Clinical Treatment Outcomes among Patients with Dermatophytosis: A Cross-Sectional Study. Naogaon Medical College Journal. 2026. doi:10.70818/nmcj.v03i01.028
BibTeX
@article{Zaman2026,
author = {Zaman, Shaila and Sattar, Md Abdus and Sumsuzzoha, SM},
title = {Antifungal Susceptibility Patterns and Clinical Treatment Outcomes among Patients with Dermatophytosis: A Cross-Sectional Study},
journal = {Naogaon Medical College Journal},
year = {2026},
doi = {10.70818/nmcj.v03i01.028}
}
EUVIMED